In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US probing J&J's marketing activities of pain drug Nucynta

This article was originally published in Scrip

Executive Summary

Janssen Pharmaceuticals received a subpoena from the Office of Inspector General (OIG) at the Department of Health and Human Services seeking documents and information about the sales, marketing and promotional practices, including any remuneration of healthcare providers, related to the immediate- and extended-release formulations of the firm's chronic pain drug Nucynta (tapentadol), the firm's parent company, Johnson & Johnson, disclosed in a Securities & Exchange Commission filing late last week.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts